1[1]GOODRIEND T L,ELLIOTT M E,CATT K J.Angiotensin receptors and their antagonists[J].NEngl J Med,1996,334:1649-1654. 被引量：1
2[2]LIU G Z,HU D Y,TAO P.The suggest for clinical examination evaluation method in cardio-vascular drug[J].Chin J Cardiol(中华心血管病杂志),1998,26 (5):336-338. 被引量：1
3[3]Committee to Revise the 1999 Chinese Guideline for the Prevention and Treatment of Patients with Hypertension.2004 update:Chinese guideline for the prevention and treatment of patients with hypertension(practical edition)[J].Chin J Cardiol(中华心血管病杂志),2004,32(12) 1060-1063. 被引量：1
4Verdecchia P,Schillaci G,Borgioni C,et al.Adrerse prognostic significance of concentiric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass[J].J Am coll cardiol,1995,25:871-878. 被引量：1
5Ambrose J,Pribhnow DG,Yao Z,et al.Angiotensin type I receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastotic function in the remodeling post-myocardial infarction ventricle[J].J Am Soc Nephrol,1999,10:129-136. 被引量：1
6Packer M,Oconnor CM,Ghali JK,et al.Effect of amlodipine on morbidity and mortality in severe chronic heart failure.Prospective randomized amlodipine survival evaluation study group[J].N Engl J Med,1996,335 (15):1107-1114. 被引量：1
4Reynolds K,Gu D,Muntner P,et al. Geographic variations in the prevalence awareness, treatment and control of hypertension in China[J]. J Hypertens,2003,21(7) : 1273-1281. 被引量：1
